Tercica (Paperback)


Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Tercica, Inc., is a biopharmaceutical company based in Brisbane, California, USA. It is owned by Ipsen. It is the current developer of Increlex (mecasermin rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica has applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth faiulre, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex is currently in Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.

R975

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles9750
Mobicred@R91pm x 12* Mobicred Info
Free Delivery
Delivery AdviceOut of stock

Toggle WishListAdd to wish list
Review this Item

Product Description

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Tercica, Inc., is a biopharmaceutical company based in Brisbane, California, USA. It is owned by Ipsen. It is the current developer of Increlex (mecasermin rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica has applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth faiulre, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex is currently in Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Duct Publishing

Country of origin

United States

Release date

June 2012

Availability

Supplier out of stock. If you add this item to your wish list we will let you know when it becomes available.

First published

June 2012

Editors

Dimensions

229 x 152 x 5mm (L x W x T)

Format

Paperback - Trade

Pages

76

ISBN-13

978-6201191730

Barcode

9786201191730

Categories

LSN

6201191739



Trending On Loot